Digestive Diseases and Sciences

, Volume 63, Issue 8, pp 2094–2104 | Cite as

Screening and Surveillance for Barrett’s Esophagus: Is It Cost-Effective?

  • John M. Inadomi
  • Nina Saxena


The cost-effectiveness of screening and surveillance for Barrett’s esophagus continues to evolve as the incidence of esophageal adenocarcinoma increases, biomarkers enhance the identification of individuals at highest risk for developing cancer, and endoscopic eradication of Barrett’s esophagus improves. Screening to detect Barrett’s esophagus may be cost-effective in selected high-risk groups based on age, race, sex and other factors such as symptoms of heartburn. Currently, endoscopic eradication therapy for Barrett’s esophagus and high-grade dysplasia is a cost-effective intervention, while endoscopic therapy for non-dysplastic Barrett’s esophagus is not a cost-effective strategy. As diagnosis of low-grade dysplasia improves, endoscopic eradication therapy may also prove to be a cost-effective intervention.


Mass screening Endoscopy Surveillance Cost-effectiveness Economic analysis Barrett’s esophagus Esophageal adenocarcinoma 


Compliance with ethical standards

Conflict of interest

John M. Inadomi is on the scientific advisory board for Cernostics, and receives research support from Ninepoint.


  1. 1.
    Shaheen NJ, Falk GW, Iyer PG, Gerson LB. American College of G. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol.. 2016;111:30–50. quiz 51.CrossRefPubMedGoogle Scholar
  2. 2.
    Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.CrossRefPubMedGoogle Scholar
  3. 3.
    Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1172–1177.CrossRefPubMedGoogle Scholar
  4. 4.
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253–1258.CrossRefPubMedGoogle Scholar
  5. 5.
    Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1339–1341.CrossRefPubMedGoogle Scholar
  6. 6.
    Inadomi JM. Cost considerations in implementing a screening and surveillance strategy for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29:51–63.CrossRefPubMedGoogle Scholar
  7. 7.
    Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.Google Scholar
  8. 8.
    Laureys S, Pellas F, Van Eeckhout P, et al. The locked-in syndrome: what is it like to be conscious but paralyzed and voiceless? In: Laureys S, ed. Progress in brain research, vol. 150. Amsterdam: Elsevier; 2005:495–611.Google Scholar
  9. 9.
    Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis : methods for quantitative synthesis in medicine. 2nd ed. New York: Oxford University Press; 2000.Google Scholar
  10. 10.
    Box GEP, Draper NR. Empirical model-building and response surfaces. New York: Wiley; 1987.Google Scholar
  11. 11.
    Saxena N, Inadomi JM. Effectiveness and cost-effectiveness of endoscopic screening and surveillance. Gastrointest Endosc Clin N Am. 2017;27:397–421.CrossRefPubMedGoogle Scholar
  12. 12.
    Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176–186.CrossRefPubMedGoogle Scholar
  13. 13.
    Nietert PJ, Silverstein MD, Mokhashi MS, et al. Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc. 2003;57:311–318.CrossRefPubMedGoogle Scholar
  14. 14.
    Gerson LB, Groeneveld PW, Triadafilopoulos G. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2004;2:868–879.CrossRefPubMedGoogle Scholar
  15. 15.
    Rubenstein JH, Inadomi JM, Brill JV, Eisen GM. Cost utility of screening for Barrett’s esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol. 2007;5:312–318.CrossRefPubMedGoogle Scholar
  16. 16.
    Gerson L, Lin OS. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett’s esophagus. Clin Gastroenterol Hepatol. 2007;5:319–325.CrossRefPubMedGoogle Scholar
  17. 17.
    Gupta N, Bansal A, Wani SB, Gaddam S, Rastogi A, Sharma P. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc. 2011;74:610–624. e612.CrossRefPubMedGoogle Scholar
  18. 18.
    Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology. 2013;144:62–73. e66.CrossRefPubMedGoogle Scholar
  19. 19.
    Heberle CR, Omidvari AH, Ali A, et al. Cost effectiveness of screening patients with gastroesophageal reflux disease for barrett’s esophagus with a minimally invasive cell sampling device. Clin Gastroenterol Hepatol. 2017;15:1397–1404.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Comay D, Blackhouse G, Goeree R, Armstrong D, Marshall JK. Photodynamic therapy for Barrett’s esophagus with high-grade dysplasia: a cost-effectiveness analysis. Can J Gastroenterol. 2007;21:217–222.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett’s esophagus with high grade dysplasia. Dig Dis Sci. 2003;48:1273–1283.CrossRefPubMedGoogle Scholar
  22. 22.
    Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett’s oesophagus? A cost effectiveness analysis. Gut. 2004;53:1736–1744.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett’s esophagus. Gastrointest Endosc. 2004;60:739–756.CrossRefPubMedGoogle Scholar
  24. 24.
    Boger PC, Turner D, Roderick P, Patel P. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett’s oesophagus. Aliment Pharmacol Ther. 2010;32:1332–1342.CrossRefPubMedGoogle Scholar
  25. 25.
    Hu Y, Puri V, Shami VM, Stukenborg GJ, Kozower BD. Comparative effectiveness of esophagectomy versus endoscopic treatment for esophageal high-grade dysplasia. Ann Surg. 2016;263:719–726.CrossRefPubMedGoogle Scholar
  26. 26.
    Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2012;143:567–575.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009;136:2101–2114. e2101–2106.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Pohl H, Sonnenberg A, Strobel S, Eckardt A, Rosch T. Endoscopic versus surgical therapy for early cancer in Barrett’s esophagus: a decision analysis. Gastrointest Endosc. 2009;70:623–631.CrossRefPubMedGoogle Scholar
  29. 29.
    Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:237–249.CrossRefPubMedGoogle Scholar
  30. 30.
    von Rahden BH, Stein HJ, Weber A, et al. Critical reappraisal of current surveillance strategies for Barrett’s esophagus: analysis of a large German Barrett’s database. Dis Esophagus. 2008;21:685–689.CrossRefGoogle Scholar
  31. 31.
    Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.CrossRefPubMedGoogle Scholar
  32. 32.
    Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:U1179–U1590.CrossRefGoogle Scholar
  33. 33.
    Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc. 1999;50:23–26.CrossRefPubMedGoogle Scholar
  34. 34.
    Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol. 1988;19:166–178.CrossRefPubMedGoogle Scholar
  35. 35.
    Kastelein F, van Olphen S, Steyerberg EW, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2015;64:864–871.CrossRefPubMedGoogle Scholar
  36. 36.
    Guarner-Argente C, Buoncristiano T, Furth EE, Falk GW, Ginsberg GG. Long-term outcomes of patients with Barrett’s esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc. 2013;77:190–199.CrossRefPubMedGoogle Scholar
  37. 37.
    Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030–1036.CrossRefPubMedGoogle Scholar
  39. 39.
    Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.CrossRefPubMedGoogle Scholar
  40. 40.
    Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–244. quiz e232.CrossRefPubMedGoogle Scholar
  41. 41.
    Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368–378.CrossRefPubMedGoogle Scholar
  42. 42.
    di Pietro M, Alzoubaidi D, Fitzgerald RC. Barrett’s Esophagus and cancer risk: how research advances can impact clinical practice. Gut Liver. 2014;8:356–370.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Rubenstein JH, Vakil N, Inadomi JM. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2005;22:135–146.CrossRefPubMedGoogle Scholar
  44. 44.
    Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett’s metaplastic epithelium. Cancer Res. 2001;61:8284–8289.PubMedGoogle Scholar
  45. 45.
    Alvi MA, Liu X, O’Donovan M, et al. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett’s esophagus. Clin Cancer Res. 2013;19:878–888.CrossRefPubMedGoogle Scholar
  46. 46.
    Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 2009;69:4112–4115.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Kaz AM, Wong CJ, Luo Y, et al. DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics. 2011;6:1403–1412.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45:478–486.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839–2848.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071–3083.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Gordon LG, Mayne GC, Hirst NG, et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc.. 2014;79:242–256. e246.CrossRefPubMedGoogle Scholar
  54. 54.
    Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of aspirin chemoprevention for Barrett’s esophagus. J Natl Cancer Inst. 2004;96:316–325.CrossRefPubMedGoogle Scholar
  55. 55.
    Choi SE, Perzan KE, Tramontano AC, Kong CY, Hur C. Statins and aspirin for chemoprevention in Barrett’s esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila). 2014;7:341–350.CrossRefGoogle Scholar
  56. 56.
    Sonnenberg A, Fennerty MB. Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology. 2003;124:1758–1766.CrossRefPubMedGoogle Scholar
  57. 57.
    Das A, Wells C, Kim HJ, Fleischer DE, Crowell MD, Sharma VK. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett’s esophagus. Endoscopy. 2009;41:400–408.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Gastroenterology, Department of MedicineUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations